INTRODUCTION
There is considerable evidence that the quality of medical care in general, 1 and oncology care in particular, 2 may be suboptimal. Standardized measurement and reporting of this quality is critical if it is to be improved. Measurement must allow comparisons among practices and over time 3 and also provide evidence of appropriate care. 4 To foster quality improvement, the Center for Medicare and Medicaid Services (CMS) introduced the Physician Quality Reporting System, which provides a small incentive payment in exchange for reporting on quality measures. Although up to 40% of physicians now participate in the Physician Quality Reporting System, half reported that they believe it has no impact on quality. 5 However, the Affordable Care Act requires that physicians report on similar measures. 6, 7 The American Society of Clinical Oncology (ASCO) Quality Oncology Practice Initiative (QOPI) provides a practice-based self-assessment measurement process to be used in the outpatient setting. 8 QOPI includes quality measures applicable to a large proportion of the patients seen in general oncology practice, 9 uses office personnel to abstract data, and is compatible with both paper-based and electronic medical records systems. Participation is voluntary and has been freely available to ASCO members since 2006. Since its inception, 510 medical practices have participated in some way during at least one round of data collection.
Many medical practice groups report that QOPI identifies areas in which improvement is desirable and helps to focus intervention. However, aggregated quality measurement averages fail to show statistically significant improvement. We hypothesized that this was related to two factors: (1) wide variation in initial practice performance, creating both wide statistical confidence intervals and varied opportunities for improvement, and (2) selective attention to only a subset of the measure set because of varied perceptions of measure importance. We undertook this analysis to determine whether QOPI provides a meaningful measurement tool that demonstrates improvement for the aggregate of participants as well as for individual practices. In addition, we wished to determine those factors associated with improvement.
METHODS
The process for measure development, the measures, patient selection, data collection methods, and the reporting process have been previously described.
8,9 QOPI, as a quality measurement and improvement tool, is exempt from oversight from institutional review boards for the protection of human patients. In institutions that have sought institutional review board assurance, the requirement for obtaining individual patient informed consent has been waived.
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Quality Measures
A measures workgroup developed the quality measures, aspiring to give goals to create measures that are (1) applicable to ambulatory oncology practices, (2) intuitively collected, (3) based on medical records abstraction, (4) amenable to improvement, and (5) relevant and important to care. The current measures are divided into seven modules concerning the following domains: (1) core measures, which address diagnosis and staging as well as treatment planning, (2) end-of-life care, (3) symptom/toxicity management, (4) NHL [non-Hodgkin lymphoma], (5) breast cancer, (6) colorectal cancer, and (7) NSCLC [non-small-cell lung cancer]. Current measures are listed on the QOPI Web site.
The measure set is reviewed and updated biannually. Measures reflecting new or changing standards of care are added and measures with poor reliability are updated or retired. We therefore limited our analysis to the measures that had stable definitions over two or more data collection periods from 2006 to 2010. Three additional features of measures were examined: (1) the associated level of evidence was examined for all measures, ranging from highly evidencebased to common sense; (2) the potential for a measure to capture only medical record documentation, which itself might lead to treatment but did not reflect treatment (with 17 measures within this group, including, for example, the documentation of smoking status as opposed to the recommendation for smoking cessation counseling); and (3) the introduction of new clinical practices (including five measures that were introduced following changes in guidelines or new evidence development. These included adequate lymph node examination after surgical resection in colorectal cancer; KRAS testing when administering anti-epidermal growth factor receptor (EGFR) medication; the use of anti-EGFR medication in the presence of mutation, which was likely to render the treatment ineffective (a measure of overuse or inappropriate care); and discussion of infertility risks and fertility preservation options before chemotherapy administration in patients with intact reproductive potential.
Eligibility Criteria
Participant groups are defined as a group of practitioners with a single tax identification number and common operating procedures. They may submit data up to twice annually to QOPI after executing a Health Insurance Portability and Accountability (HIPAA) business associate agreement with ASCO. Participants included in this analysis exclusively reported on US patients, participated in at least two rounds of data collection, and submitted information on 30 or more patients per round. Programs reporting trainee care within fellowship programs were excluded.
Data Collection
Medical records were reviewed in a sequential sampling starting from the most recently seen patient and going backward through patient lists until the sample size requirement was met or until all possible medical records (eg, all medical records with a particular diagnosis) were examined. All patients must have been diagnosed with their invasive malignancy within 2 years of their first visit to the practice. Participants were required to submit data on the core domain module measures in addition to those from two additional domain modules, at a minimum. Sample sizes varied with participant practice size and ranged from a minimum of 24 medical records per the two required domain modules with core measures on all medical records, and are in no case fewer than 48 records for solo practitioners to 40 records per domain module and no fewer than 80 records for practices of seven or more physicians.
Limited patient-level data were entered via a secure Web-based tool hosted by Outcome Sciences (Cambridge, MA), which has an HIPAA compliance agreement with ASCO. Participants were also asked to report information about their practices, including specialty type, affiliation, size, number of new patients evaluated annually, number of physicians within the practice, and location by region within the United States.
Analysis
Measure performance rates were valued from 0.0 to 1.0 and were calculated by using the number of patients eligible for a measure as the denominator and the number of patients meeting criteria for adherence to the measure as the numerator. For measures that addressed overuse (receipt of inappropriate care), this proportion was subtracted from 1 so that, for example, a 0.04 rate of overuse was expressed as a 0.96 rate of avoidance of overuse. We calculated the simple mean quality score for each of the seven domains in the initial round of data collection of each practice.
Model Development
To evaluate improvement and not total score, we adjusted the initial quality scores by creating a multivariate model of practice achievement over time. Abstraction round for the practice was held as the independent variable within the linear regression model while controlling for practice characteristics, quality measure characteristics, and the measures individually. We assessed interactions between quality measure characteristics and abstraction round to assess whether certain types of quality measures were more likely to improve over time.
RESULTS
From 2006 to 2010, 308 unique practice groups with approximately 2,100 physicians participated in at least one of the 10 possible rounds of data collection. A total of 156 groups were eligible for this analysis after practices were excluded for the following reasons: submission of fellowship data (n ϭ 22), non-US practice (n ϭ 7), submission of data on fewer than 30 patients in at least one of two rounds (n ϭ 113), and participation in a single data collection period (n ϭ 10). Table 1 presents information comparing the practices included with those not included in the analysis. There are significant differences in the criteria used for exclusion and in the frequency of missing data elements. The practices represent a wide geographic distribution throughout the United States, with 39% identifying their location as the Midwest, 14% Northeast, 27% South, and 20% West ( Table 1 ). The majority (65%) of practices were composed of only oncology specialists; 64% identified themselves as private independent practices. Forty percent evaluated between 500 and 1,500 new patients annually, although 30% saw more than 1,500 new patients and represented relatively large groups with more than 10 physicians. Practices participated in a mean of 5.06 rounds of data collection (standard deviation, 1.94). Practices excluded from analysis were significantly different from those included because of the exclusion criteria and because many practice characteristics were unreported. Table 2 presents both univariate and multivariate analysis of practice and measure characteristics and their association with improvement in quality scores. In multivariate analysis, participation in each additional round of data collection was associated with an improvement of 1.09 in the odds of adherence to quality indicators (P Ͻ .001). When initially introduced, adherence to measures reflecting a new clinical practice was, on average, lower than for other quality measures (odds ratio, 0.01; P Ͻ .001); however, these measures had greater improvement over time (odds ratio, 1.40 for the interaction of new clinical practice and abstraction round; P Ͻ .001). No other quality measure or practice characteristic was associated with improvement. Table 3 summarizes the mean adherence to quality indicators by domain from the mean of the first round of data collection for all practices, which was included in this analysis. Mean adherence to the core measures domain was 0.77 (95% CI, 0.76 to 0.79). The lowest adherence rates were in the symptom/toxicity management domain at 0.65 (95% CI, 0.61 to 0.69). For the disease-specific domains, adherence was highest for breast cancer at 0.91 (95% CI, 0.90 to 0.93) and lowest for NSCLC at 0.66 (95% CI, 0.70 to 0.72). Mean adherence to measures in the end-of-life care domain was 0.72 (95% CI, 0.70 to 0.75). Figure 2A presents measures assessing new clinical practices that demonstrated rapid improvement over time. These include measures of testing for KRAS mutations when targeted therapy was given in metastatic colon cancer, using the targeted therapy appropriately, using aprepitant when highly emetogenic therapy was given, and the number of lymph nodes examined in colectomy specimens from patients with colon cancer. Although not a new guideline or recommendation, 12 the increase in the use of aprepitant and fosprepitant occurred after the parenteral form of these medications became available in January 2008.
13 Figure 2B presents the measures of appropriate recommendations for adjuvant chemotherapy 14,15 that had high adherence at baseline approaching or exceeding 90% and relatively small variability. In Table 1 
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www.jco.org contrast, Figure 2C presents measures with a substantial gap in performance that also failed to show much improvement over time. This measure group examined documentation of appropriate smoking cessation counseling, evaluation of infertility risk, and fertility preservation counseling. Adherence to these quality measures ranged from a high of 0.34 for smoking cessation to a low of 0.06 for discussion of fertility preservation.
DISCUSSION
QOPI has been widely adopted. Because there were 13,358 ASCO members who identified themselves as US medical oncologists, the 2,100 physicians who participated represent approximately 15% of the US medical oncology workforce. The practices that participated in QOPI are likely not representative of all practices. In addition, the practices that participated but that were excluded from analysis were different from those included. There are three reasons for this. First, although the logic is circular, the exclusions for specific factors, such as inclusion of fellowship data or absence of participation in multiple rounds over time, were different. Second, on the basis of those exclusion criteria, a large number of practices simply failed to provide requested information. Third, Midwestern practices may have been overrepresented because their participation was sponsored by a payer. 16 Although quality measures associated with new clinical practices saw the largest increases in concordance, we found that, on average, the adjusted mean aggregate quality score increased meaningfully 
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from first to last round of participation. These results suggest that voluntary programs like QOPI may be one of many factors allowing for improvement in the quality of outpatient oncology care. However, it is unlikely that this measurement process itself causes the positive change. Improvement could represent overall improving practice trends that possibly reflect ongoing efforts by governmental agencies and others to increase quality assessment by physicians, or they could represent another factor such as physician desire to improve on certain (but not all) measures. The Hawthorne effect, the association of improvement with observation, is often cited as an explanation for this type of result.
17,18 However, if that were the explanation, all measures would have improved similarly. For example, quality measures addressing symptom/toxicity management and end-of-life care did not change over time.
Previous studies have shown substantial variation in the quality of cancer care. 2, 19, 20 McGlynn et al 21 demonstrated that practitioners were concordant with a composite of nine measures of care in 192 patients with breast cancer 76% of the time and 54% of the time for a composite of 12 measures for colorectal cancer. In the National Initiative for Cancer Care Quality, 82% of 6,148 patients with breast cancer and 64% of 1,342 patients with colon cancer received all care related to adjuvant therapy for which they were eligible. Although the overall achievement of "recommended care" was impressive at 86% and 78%, respectively, the range of concordance with individual quality measures ranged from 13% to 96% in breast cancer and 50% to 90% in colorectal cancer. 19 We also found wide variation in adherence to quality measures, with mean adherence in the first reported round from the practices ranging from 15% (infertility counseling) to 98% (pathology report available, appropriate adjuvant therapy for colon and rectal cancer, and appropriate use of serotonin antagonist antiemetic therapy). Similar variation in grouped measures was observed and, although this analysis was not designed to evaluate this type of difference, it was similar to that reported previously 2, 19, 20 The opportunity to achieve this improvement yet failure to do so, as shown in the examples of smoking cessation and infertility counseling, was surprising given the widespread acknowledgment of the evidence base for these interventions. 20, 22 Although this may represent documentation and not practice, it seems likely that these issues truly were not addressed in usual clinical encounters. ASCO has supported expanding networking of QOPI practices to allow collaborative improvement networks to help disseminate best practices to begin to address this issue, with participants from the National Cancer Institute Community Cancer Centers Program, 23 the Michigan Oncology Quality Consortium, 23a and the Northern New England Clinical Oncology Society.
The absence of improvement in measures that capture the appropriate recommendation of adjuvant chemotherapy within evidence-based guidelines care for lung, colon, and breast cancer 13, 14 demonstrates that perfection may not be possible or desirable and also demonstrates a known impediment to guideline adherence. 24 There likely is a limit on concordance for process-based measures because of underlying patient health status and an individual patient's approach to treatment, as well as other subtle features that prevent a provider from recommending treatment in these otherwise straightforward circumstances.
Our results must be viewed in light of several limitations. Participants in QOPI are volunteers, and it is therefore likely that they are not representative of all practices. Their high level of achievement and improvement may reflect an atypical desire for self-examination and Proportion Achieved Data Collection Round Rates of concordance over time for (A) KRAS status testing in patients receiving targeted therapy, lymph node retrieval rates in colorectal cancer, and appropriate use of aprepitant with highly emetogenic therapy; (B) guidelineappropriate recommendation for adjuvant chemotherapy in breast, colorectal, and lung cancer; (C) documentation of smoking status, smoking cessation counseling, discussion of infertility risk, and discussion of fertility preservation. (Throughout figure, black vertical lines indicate one standard deviation above andimprovement. 25 We excluded practices from our study if they submitted data on fewer than 30 patients, so our results may not be generalizable to small practices with a low volume of patients. However, 40% of the practices included in our study had just one to four physicians, so small practices were broadly represented. In addition, practices collected and entered their own data, raising potential questions regarding data validity. However, if result reporting was influenced in this manner, one would expect to see dramatic improvements across all quality measures.
It is important to note that we have focused on process measures and generally have not been able to evaluate true patient outcomes. Although we are aware of the hierarchy of quality measures and the importance of outcome measures, 26 we are also aware that the small numbers of events and long time from treatments to outcomes such as death may make this important type of measure less than a completely reliable discriminator of quality. 27 Medical record documentation may not reliably represent care given to patients, 28 and because the QOPI process is based entirely on medical record review, it may not accurately capture care itself. Finally, it is not possible to determine whether QOPI is contributing to the improvement in quality of care in participating practices or if it is simply documenting an existing trend in the quality of cancer care.
In summary, QOPI provides a structure for oncology practice group self-examination that has been widely adopted and shows practice improvement over time. The absence of improvement in which wide performance gaps remain in some specific areas demonstrates the opportunity to cross the quality chasm. The development of tools and incentives to inspire this improvement are obvious and important next steps. 
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